Cellceutix Corp. (CTIX.OB) Continues Progress Towards Phase 1 Human Trials for Kevetrin™
Cellceutix Corporation issued a press release yesterday to announce that they have filed U.S. and foreign patent applications that cover pharmaceutical formulations of their compound Kevetrin™, which is being developed as a treatment for drug-resistant cancers. The patent applications not only cover Kevetrin as a treatment for cancer, but a variety of other areas and also cover many other unique compounds that have similar structures which Cellceutix may later choose to develop also. George Evans, Chief Executive Officer of Cellceutix, was quoted as saying, "This filing should give us a strong patent position in the major markets around the world."…